Table 3 Histopathological data comparing patients who underwent radical resections following NACT (n = 126) from group 1 with patients who underwent upfront surgery (n = 62) from group 2
From: D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy
Resected patients from group 1 (n = 126) | Resected patients from group 2 (n = 62) | |
|---|---|---|
Final pathology | ||
Carcinoma in situ | - | 1 (2%) |
Well-differentiated adenocarcinoma | 4 (3%) | 5 (8%) |
Moderately-differentiated adenocarcinoma | 27 (21%) | 17 (27%) |
Poorly differentiated adenocarcinoma | 57 (45%) | 33 (53%) |
Signet ring cell adenocarcinoma | 16 (13%) | 6 (10%) |
Microscopic foci of adenocarcinoma | 7 (6%) | - |
No residual tumor | 15 (12%) | - |
T-stage | ||
T1 | 9 | 10 |
T2 | 26 | 14 |
T3 | 54 | 18 |
T4 | 20 | 20 |
Perineural invasion present | 22 (17%) | 9 (14.5%) |
Lymphovascular invasion present | 45 (36%) | 36 (58%) |
Median number of lymph nodes harvested (range) | 16 (1 to 53) | 18 (3 to 39) |
Median number of positive nodes (range) | 1 (0 to 22) | 2 (0 to 22) |
Lymph node ratio (range) | 0.07 (0 to 1.0) | 0.14 (0 to 0.95) |